Vivitonin® 50 mg tablets Vivitonin® 100 mg tablets Species: Dogs Therapeutic indication: Pharmaceuticals: Cardiovascular and respiratory preparations Active ingredient: Propentofylline Product:Vivitonin® 50 mg tablets and Vivitonin® 100 mg tablets Product index: Vivitonin® 50 mg and 100 mg tablets Qualitative and quantitative composition Vivitonin 50 mg tablets: Active substance: Propentofylline 50.00 mg/tablet Film coating ingredients: Yellow ferric oxide (E172) (colouring) 0.125 mg/tablet Titanium Dioxide (E171) (colouring) 0.359 mg/tablet Vivitonin 100mg tablets: Active substance: Propentofylline 100.00 mg/tablet Film coating ingredients: Yellow ferric oxide (E172) (colouring) 0.258 mg/tablet Titanium Dioxide (E171) (colouring) 0.856 mg/tablet For the full list of excipients, see section “Pharmaceutical particulars”. Pharmaceutical form Vivitonin 50 mg tablets: Orange-yellow film coated tablets. Vivitonin 100 mg tablets: Ochre, biconvex, oblong filmcoated tablets. Clinical particulars Target Species Dogs. Indications for use For improvement in dullness, lethargy and overall demeanour in dogs. Vivitonin is particularly useful in older dogs, where it may increase willingness to exercise and exercise tolerance. Contraindications Not to be administered to pregnant bitches or breeding animals. Do not use in animals with known hypersensitivity to the active substance or any of the excipients. Special warnings for each target species None. Special precautions for use Specific diseases (e.g. kidney disease) should be treated accordingly. In the case of renal failure, the dose should be reduced. Consideration should be given to rationalising the medication of dogs already receiving treatment for congestive heart failure or bronchial disease. Operator warnings Care should be taken to avoid accidental ingestion. Wash hands after use. Adverse Reactions Vomiting has been observed on rare occasions, particularly at the commencement of therapy. In rare cases allergic reactions (e.g. urticaria) may occur and these necessitate discontinuation of the treatment. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). Use during pregnancy or lactation Do not use in pregnant bitches as the product has not been evaluated in these animals. Interactions None known. Amounts to be administered and administration route Vivitonin 50 mg tablets: Half a tablet per 5 kg body weight twice a day (equivalent to 6-10 mg propentofylline per kg bodyweight per day). Dogs of less than 5 kg may receive a quarter of a tablet twice a day. Dogs of more than 20 kg can be given Vivitonin 100mg tablets. The tablets can be administered directly onto the back of the dog's tongue or can be mixed in a small ball of food and should be administered at least 30 minutes before feeding. Divide the tablets in halves and quarters with a knife or with a tablet splitter. Vivitonin 100 mg tablets: Half a tablet per 10kg body weight twice a day The tablets should not be quartered. More accurate dosing may be achieved using a combination of 100 mg and 50 mg tablets. Dogs of less than 20 kg can be given 50 mg tablets. The tablets can be administered directly onto the back of the dog's tongue or can be mixed in a small ball of food and should be administered at least 30 minutes before feeding. Divide the tablets in halves with a knife or with a tablet splitter. Overdose Symptoms of cardiac and cerebral overstimulation have been observed. In such cases, animals should be treated symptomatically. Withdrawal periods Not applicable.